Is ANNX or ORGO more profitable?

Annexon has a net margin of 0.00% compared to Organogenesis' net margin of -19.94%. Organogenesis' return on equity of -23.89% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Annexon N/A -106.15% -79.82% Organogenesis -19.94% -23.89% -11.13%

Organogenesis (ORGO) Competitors

$1.80 -0.04 (-2.17%)

As of 08/21/2026 04:00 PM Eastern

Compare

ORGO vs. SLDB, ABUS, DSGN, KURA, and ANNX

Should you buy Organogenesis stock or one of its competitors? Organogenesis's main competitors and comparable companies include Solid Biosciences (SLDB), Arbutus Biopharma (ABUS), Design Therapeutics (DSGN), Kura Oncology (KURA), and Annexon (ANNX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Organogenesis compare to Solid Biosciences?

Organogenesis (NASDAQ:ORGO) and Solid Biosciences (NASDAQ:SLDB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Organogenesis has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$564.17M	0.41	$37.03M	-$0.86	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A

Organogenesis currently has a consensus target price of $4.33, indicating a potential upside of 140.74%. Solid Biosciences has a consensus target price of $17.40, indicating a potential upside of 87.10%. Given Organogenesis' higher possible upside, analysts plainly believe Organogenesis is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

49.6% of Organogenesis shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 18.8% of Organogenesis shares are owned by insiders. Comparatively, 2.7% of Solid Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Organogenesis has a beta of 1.34, suggesting that its share price is 34% more volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.41, suggesting that its share price is 141% more volatile than the broader market.

In the previous week, Solid Biosciences had 5 more articles in the media than Organogenesis. MarketBeat recorded 5 mentions for Solid Biosciences and 0 mentions for Organogenesis. Solid Biosciences' average media sentiment score of 0.82 beat Organogenesis' score of 0.00 indicating that Solid Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Organogenesis	Neutral
Solid Biosciences	Positive

Solid Biosciences has a net margin of 0.00% compared to Organogenesis' net margin of -19.94%. Organogenesis' return on equity of -23.89% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organogenesis	-19.94%	-23.89%	-11.13%
Solid Biosciences	N/A	-71.35%	-60.58%

Summary

Organogenesis beats Solid Biosciences on 8 of the 15 factors compared between the two stocks.

How does Organogenesis compare to Arbutus Biopharma?

Arbutus Biopharma (NASDAQ:ABUS) and Organogenesis (NASDAQ:ORGO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

Arbutus Biopharma has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market. Comparatively, Organogenesis has a beta of 1.34, indicating that its share price is 34% more volatile than the broader market.

Organogenesis has higher revenue and earnings than Arbutus Biopharma. Organogenesis is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	73.21	-$33.50M	$0.79	6.59
Organogenesis	$564.17M	0.41	$37.03M	-$0.86	N/A

In the previous week, Arbutus Biopharma had 9 more articles in the media than Organogenesis. MarketBeat recorded 9 mentions for Arbutus Biopharma and 0 mentions for Organogenesis. Arbutus Biopharma's average media sentiment score of 0.80 beat Organogenesis' score of 0.00 indicating that Arbutus Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Arbutus Biopharma	Positive
Organogenesis	Neutral

Arbutus Biopharma has a net margin of 84.22% compared to Organogenesis' net margin of -19.94%. Arbutus Biopharma's return on equity of 90.98% beat Organogenesis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	84.22%	90.98%	82.34%
Organogenesis	-19.94%	-23.89%	-11.13%

43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 49.6% of Organogenesis shares are owned by institutional investors. 19.9% of Arbutus Biopharma shares are owned by company insiders. Comparatively, 18.8% of Organogenesis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Arbutus Biopharma presently has a consensus target price of $5.00, indicating a potential downside of 4.03%. Organogenesis has a consensus target price of $4.33, indicating a potential upside of 140.74%. Given Organogenesis' higher possible upside, analysts clearly believe Organogenesis is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Arbutus Biopharma beats Organogenesis on 11 of the 16 factors compared between the two stocks.

How does Organogenesis compare to Design Therapeutics?

Organogenesis (NASDAQ:ORGO) and Design Therapeutics (NASDAQ:DSGN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

Organogenesis has higher revenue and earnings than Design Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Organogenesis	$564.17M	0.41	$37.03M	-$0.86	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.18	N/A

In the previous week, Organogenesis' average media sentiment score of 0.00 equaled Design Therapeutics'average media sentiment score.

Company	Overall Sentiment
Organogenesis	Neutral
Design Therapeutics	Neutral

Design Therapeutics has a net margin of 0.00% compared to Organogenesis' net margin of -19.94%. Organogenesis' return on equity of -23.89% beat Design Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Organogenesis	-19.94%	-23.89%	-11.13%
Design Therapeutics	N/A	-34.03%	-32.05%

Organogenesis presently has a consensus price target of $4.33, suggesting a potential upside of 140.74%. Design Therapeutics has a consensus price target of $16.50, suggesting a potential upside of 10.07%. Given Organogenesis' higher probable upside, analysts clearly believe Organogenesis is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

49.6% of Organogenesis shares are held by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are held by institutional investors. 18.8% of Organogenesis shares are held by company insiders. Comparatively, 17.1% of Design Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Organogenesis has a beta of 1.34, indicating that its stock price is 34% more volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.63, indicating that its stock price is 63% more volatile than the broader market.

Summary

Organogenesis beats Design Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Organogenesis compare to Kura Oncology?

Kura Oncology (NASDAQ:KURA) and Organogenesis (NASDAQ:ORGO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, media sentiment, valuation and earnings.

Organogenesis has higher revenue and earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$67.48M	15.67	-$278.67M	-$3.37	N/A
Organogenesis	$564.17M	0.41	$37.03M	-$0.86	N/A

49.6% of Organogenesis shares are held by institutional investors. 7.6% of Kura Oncology shares are held by company insiders. Comparatively, 18.8% of Organogenesis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Organogenesis has a net margin of -19.94% compared to Kura Oncology's net margin of -384.30%. Organogenesis' return on equity of -23.89% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-384.30%	-207.18%	-45.17%
Organogenesis	-19.94%	-23.89%	-11.13%

Kura Oncology currently has a consensus price target of $25.62, suggesting a potential upside of 115.44%. Organogenesis has a consensus price target of $4.33, suggesting a potential upside of 140.74%. Given Organogenesis' higher possible upside, analysts plainly believe Organogenesis is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Kura Oncology has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Organogenesis has a beta of 1.34, meaning that its stock price is 34% more volatile than the broader market.

In the previous week, Kura Oncology had 17 more articles in the media than Organogenesis. MarketBeat recorded 17 mentions for Kura Oncology and 0 mentions for Organogenesis. Kura Oncology's average media sentiment score of 0.79 beat Organogenesis' score of 0.00 indicating that Kura Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Kura Oncology	Positive
Organogenesis	Neutral

Summary

Organogenesis beats Kura Oncology on 11 of the 16 factors compared between the two stocks.

How does Organogenesis compare to Annexon?

Annexon (NASDAQ:ANNX) and Organogenesis (NASDAQ:ORGO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

In the previous week, Annexon had 6 more articles in the media than Organogenesis. MarketBeat recorded 6 mentions for Annexon and 0 mentions for Organogenesis. Annexon's average media sentiment score of 0.51 beat Organogenesis' score of 0.00 indicating that Annexon is being referred to more favorably in the media.

Company	Overall Sentiment
Annexon	Positive
Organogenesis	Neutral

Organogenesis has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annexon	N/A	N/A	-$206.69M	-$1.16	N/A
Organogenesis	$564.17M	0.41	$37.03M	-$0.86	N/A

Annexon presently has a consensus target price of $15.33, suggesting a potential upside of 202.43%. Organogenesis has a consensus target price of $4.33, suggesting a potential upside of 140.74%. Given Annexon's stronger consensus rating and higher probable upside, equities research analysts clearly believe Annexon is more favorable than Organogenesis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annexon	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Annexon has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market. Comparatively, Organogenesis has a beta of 1.34, suggesting that its stock price is 34% more volatile than the broader market.

Annexon has a net margin of 0.00% compared to Organogenesis' net margin of -19.94%. Organogenesis' return on equity of -23.89% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annexon	N/A	-106.15%	-79.82%
Organogenesis	-19.94%	-23.89%	-11.13%

49.6% of Organogenesis shares are held by institutional investors. 10.3% of Annexon shares are held by insiders. Comparatively, 18.8% of Organogenesis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Organogenesis beats Annexon on 9 of the 15 factors compared between the two stocks.

Get Organogenesis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ORGO vs. The Competition

Export

Metric	Organogenesis	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$231.62M	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-2.09	11.62	272.60	24.24
Price / Sales	0.41	1,338.17	618.96	99.81
Price / Cash	2.78	105.14	78.62	53.99
Price / Book	1.57	16.80	13.05	6.20
Net Income	$37.03M	-$12.50M	$3.47B	$348.59M
7 Day Performance	0.56%	3.29%	2.09%	0.08%
1 Month Performance	-25.93%	8.23%	6.64%	3.88%
1 Year Performance	-63.19%	55.05%	25.02%	16.98%

Organogenesis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ORGO Organogenesis	1.1562 of 5 stars	$1.80 -2.2%	$4.33 +140.7%	-63.2%	$231.62M	$564.17M	N/A	950	Analyst Downgrade
SLDB Solid Biosciences	2.4061 of 5 stars	$8.84 +3.3%	$17.11 +93.6%	+56.8%	$927.05M	N/A	N/A	100	News Coverage Analyst Forecast Gap Up
ABUS Arbutus Biopharma	1.271 of 5 stars	$4.68 +1.9%	$5.00 +7.0%	+45.1%	$923.50M	$14.08M	5.63	90	News Coverage Buyback Announcement Gap Up
DSGN Design Therapeutics	0.7597 of 5 stars	$14.40 +0.5%	$16.50 +14.6%	+185.0%	$899.90M	N/A	N/A	40	Positive News
KURA Kura Oncology	3.1502 of 5 stars	$9.92 +0.7%	$25.46 +156.6%	+55.4%	$880.16M	$67.48M	N/A	130	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ORGO) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Organogenesis (ORGO) Competitors

ORGO vs. SLDB, ABUS, DSGN, KURA, and ANNX

How does Organogenesis compare to Solid Biosciences?

Summary

How does Organogenesis compare to Arbutus Biopharma?

Summary

How does Organogenesis compare to Design Therapeutics?

Summary

How does Organogenesis compare to Kura Oncology?

Summary

How does Organogenesis compare to Annexon?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGO vs. The Competition

Organogenesis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Organogenesis (ORGO) Competitors

ORGO vs. SLDB, ABUS, DSGN, KURA, and ANNX

How does Organogenesis compare to Solid Biosciences?

Which has better valuation & earnings, ORGO or SLDB?

Do analysts recommend ORGO or SLDB?

Do insiders & institutionals believe in ORGO or SLDB?

Which has more risk & volatility, ORGO or SLDB?

Does the media favor ORGO or SLDB?

Is ORGO or SLDB more profitable?

Summary

How does Organogenesis compare to Arbutus Biopharma?

Which has more risk and volatility, ABUS or ORGO?

Which has better earnings & valuation, ABUS or ORGO?

Does the media prefer ABUS or ORGO?

Is ABUS or ORGO more profitable?

Do insiders and institutionals believe in ABUS or ORGO?

Do analysts recommend ABUS or ORGO?

Summary

How does Organogenesis compare to Design Therapeutics?

Which has stronger earnings & valuation, ORGO or DSGN?

Does the media refer more to ORGO or DSGN?

Is ORGO or DSGN more profitable?

Do analysts rate ORGO or DSGN?

Do insiders and institutionals have more ownership in ORGO or DSGN?

Which has more volatility and risk, ORGO or DSGN?

Summary

How does Organogenesis compare to Kura Oncology?

Which has preferable earnings and valuation, KURA or ORGO?

Do institutionals and insiders have more ownership in KURA or ORGO?

Is KURA or ORGO more profitable?

Do analysts rate KURA or ORGO?

Which has more volatility and risk, KURA or ORGO?

Does the media prefer KURA or ORGO?

Summary

How does Organogenesis compare to Annexon?

Does the media prefer ANNX or ORGO?

Which has higher earnings & valuation, ANNX or ORGO?

Do analysts recommend ANNX or ORGO?

Which has more volatility & risk, ANNX or ORGO?

Is ANNX or ORGO more profitable?

Do insiders & institutionals hold more shares of ANNX or ORGO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGO vs. The Competition

Organogenesis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools